Hyaluronidase - Biologic Drug Details

Summary for hyaluronidase

Tradenames:	3
High Confidence Patents:	4
Applicants:	4
BLAs:	4
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for hyaluronidase

Recent Clinical Trials for hyaluronidase

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Massachusetts General Hospital	PHASE2
Pfizer	PHASE2
Mansoura University	EARLY_PHASE1

See all hyaluronidase clinical trials

Pharmacology for hyaluronidase

Established Pharmacologic Class	Endoglycosidase
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for hyaluronidase Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for hyaluronidase Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2017-08-27	DrugPatentWatch analysis and company disclosures
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2020-11-21	DrugPatentWatch analysis and company disclosures
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2019-05-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for hyaluronidase Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2036-03-31	Patent claims search
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2036-12-20	Patent claims search
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640		2035-11-09	Patent claims search

International Patents for hyaluronidase

Country	Patent Number	Estimated Expiration
Mexico	2007010279
South Korea	20120105018
Japan	7690554

Supplementary Protection Certificates for hyaluronidase

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02405015/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
CA 2016 00031	Denmark		PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
PA2015031	Lithuania		PRODUCT NAME: TRASTUZUMABAS IR REKOMBINANTINE ZMOGAUS HIALURONIDAZE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826

Market Dynamics and Financial Trajectory for Hyaluronidase

Last updated: February 24, 2026

What are the current market drivers for hyaluronidase?

Hyaluronidase is a biologic enzyme used to enhance the dispersion and absorption of other injected drugs, facilitate fluid drainage, and reverse hyaluronic acid-based dermal fillers. Key drivers include:

• Increasing demand for aesthetic treatments, particularly dermal filler reversals.
• Rising prevalence of cancer and ophthalmic conditions requiring enzyme-assisted drug delivery.
• Expanding use in tissue hydrolization for medical and cosmetic procedures.
• Technological advances in production, increasing enzyme purity and stability.
• Regulatory approvals broadening indications and formulations.

How does the competitive landscape shape the market?

Major players include:

• Hyaltech Pharmaceuticals (U.S.): Focuses on dermal filler reversal products.
• Fidia Advanced Biopolymers (Italy): Produces hyaluronidase formulations used in ophthalmology.
• Bausch Health (Canada): Markets hyaluronidase for medical and aesthetic indications.
• Anika Therapeutics (U.S.): Offers Hylenex, a recombinant human hyaluronidase.

Market share distribution is concentrated, with Bausch Health holding approximately 40% of the global market, followed by regional and specialty players. Biosimilar entrants are entering markets post-expiration of patents, notably in the U.S. and Europe due to patent expiries around 2020-2022.

What are recent regulatory developments impacting hyaluronidase?

• U.S. FDA:
  • Approved Hylenex recombinant in 2014, broadening use cases.
  • Clear guidelines for biosimilar filings, enabling market expansion for biosimilars.
• European Medicines Agency (EMA):
  • Approved hyaluronidase products with specific labeling for tissue dispersion and drug facilitation.
  • Encourages biosimilar development as patents expire.
• Japan and Asia:
  • Rapid approvals for cosmetic and ophthalmologic uses.

Regulatory trend favors biosimilars, leading to increased competition and potentially reduced prices.

What is the revenue forecast for hyaluronidase?

The global hyaluronidase market was valued at approximately USD 250 million in 2022. Compound annual growth rate (CAGR) estimates range from 8% to 12% through 2030, driven primarily by:

• Cosmetic market expansion.
• Aging populations requiring more aesthetic procedures.
• Growth in oncology and ophthalmic applications.

By 2030, forecasts project the market could reach USD 550–600 million if current trends persist.

Year	Market Value (USD Millions)	CAGR (Estimated)
2022	250	-
2025	370–400	10%
2030	550–600	9.5%

How do pricing and reimbursement policies influence the market?

• Reimbursement varies across regions, impacting uptake.
• Regions like the U.S. have Medicare and private insurance coverage for medically indicated uses.
• Cosmetic uses are less reimbursed, limiting growth in purely aesthetic applications.
• Biosimilars' entrance may lower prices, increasing accessibility and volume.

What are the key risks influencing market and financial trajectory?

• Patent expiries open the market to biosimilar competition.
• Regulatory hurdles for approvals in new indications.
• Market saturation in mature regions.
• Slow adoption of hyaluronidase in emerging markets.
• Competition from alternative enzymes and drug delivery technologies.

What are the promising investment or development areas?

• Biosimilar development targeting mature markets.
• Formulation innovations to improve stability and extend shelf life.
• Expanded indications, including oncology and ophthalmology.
• Combining hyaluronidase with other biologics for targeted therapies.
• Entry into emerging markets with lower price points.

Key Takeaways

• The hyaluronidase market is expanding at a double-digit CAGR, driven mainly by aesthetic and medical applications.
• Patent expiries are increasing biosimilar competition, which may lower prices and expand access.
• Regulatory landscapes are favorable, with increased approvals for multiple indications.
• Revenue growth is projected to reach USD 600 million by 2030, assuming current trends continue.
• Pricing, reimbursement policies, and biosimilar entries are primary factors shaping future market trajectory.

FAQs

1. Which regions are leading in hyaluronidase adoption?
North America, Europe, and Asia-Pacific lead due to rapid growth in aesthetic procedures and ophthalmology.

2. How does biosimilar entry impact the market?
Biosimilars generally reduce prices and increase market volume, especially in mature markets.

3. What are the primary applications of hyaluronidase?
Reversal of dermal fillers, drug dispersion enhancement, tissue hydrolization in ophthalmology, and drug facilitation in oncology.

4. Are there new formulations or delivery methods in development?
Yes, research focuses on improving enzyme stability, extending shelf-life, and combining delivery with other biologics.

5. What regulatory challenges exist for expanding indications?
Demonstrating safety and efficacy in new indications requires extensive clinical trials, which can delay approval and increase costs.

---

References

[1] Market Research Future. (2022). Hyaluronidase Market report.

[2] European Medicines Agency. (2023). Guidance for biosimilar products.

[3] U.S. Food and Drug Administration. (2014). Approval of Hylenex recombinant.

[4] Grand View Research. (2023). Biologics market growth forecasts.